Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)

- The report reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics and enlists all their major and minor projects

- The report assesses Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athera Biotechnologies AB

Bayer AG

Cadrock Pty Ltd

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

Chong Kun Dang Pharmaceutical Corp

CSL ...

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athera Biotechnologies AB

Bayer AG

Cadrock Pty Ltd

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

Chong Kun Dang Pharmaceutical Corp

CSL Ltd

Cynata Therapeutics Ltd

DalCor Pharmaceuticals Inc

Gilead Sciences Inc

Hemostemix Inc

Human Stem Cells Institute

Idorsia Pharmaceutical Ltd

Kowa Co Ltd

LipimetiX Development Inc

Livzon Pharmaceutical Group Co Ltd

MedImmune LLC

Orion Corp

Proteon Therapeutics Inc

Resverlogix Corp

Reven Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

The Medicines Company

Verseon Corp

VESSL Therapeutics Ltd

ViroMed Co Ltd

Virtual Drug Development Inc

XyloCor Therapeutics Inc

Table of Contents

Table of Contents

Introduction

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Overview

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Development

Coronary Artery ...

Table of Contents

Introduction

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Overview

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Development

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Assessment

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Companies Involved in Therapeutics Development

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drug Profiles

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, ...

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Ascendia Pharmaceuticals LLC, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by AstraZeneca Plc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Athera Biotechnologies AB, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Bayer AG, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Cadrock Pty Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Capricor Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CardioVascular BioTherapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CSL Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Cynata Therapeutics Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by DalCor Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Gilead Sciences Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Hemostemix Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Human Stem Cells Institute, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Idorsia Pharmaceutical Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Kowa Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by LipimetiX Development Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by MedImmune LLC, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Orion Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Proteon Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Resverlogix Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Reven Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Supernus Pharmaceuticals Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by The Medicines Company, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Verseon Corp, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by VESSL Therapeutics Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by ViroMed Co Ltd, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Virtual Drug Development Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by XyloCor Therapeutics Inc, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H1 2019

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, ...

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports